MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
|Videos|October 21, 2021
Evolving Fellowship Training in Multiple Sclerosis
Ahmed Obeidat, MD, PhD; Jeffrey Cohen, MD; and Erin Longbrake, MD, PhD discuss the evolution of fellowship training for multiple sclerosis specialists.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Jeffrey Cohen, MD
Director, Mellen Center for Multiple Sclerosis Treatment and Research; Director, Experimental Therapeutics Program, Cleveland Clinic - Erin Longbrake, MD, PhD
Assistant Professor of Neurology; Director, Fellowship Program, Multiple Sclerosis & Other Inflammatory Brain Disease, Yale School of Medicine
Key Learning Objectives
- Fellowship training paths in multiple sclerosis
- Subspecialty certification training in multiple sclerosis
- Practical advice for the clinical care of multiple sclerosis
- The future of clinician training for multiple sclerosis care
Advertisement
Related to this article
The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.
An ACT–based group intervention did not significantly improve resilience at 3 months in patients with MS but was associated with improvements in anxiety, well-being, psychological flexibility, and health-related quality of life.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
2
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
3
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5